Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Birdshot Chorioretinopathy : Prospective Follow-up and Immunogenetic Studies(CO-BIRD)

NCT05153057 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2004-11-02
Last updated
2026-03-04

Condition(s) studied

Birdshot ChorioretinopathyPosterior Uveitis

Investigational drug(s) / intervention(s)

Observational study

Observational study: The goal of the study is purely observational. Treatment decisions will be made by physicians according to the grading of the intraocular inflammation related to birdshot chorioretinopathy and to their consequences on visual function. These treatment decisions will be independent from the observational study.

Study summary

The purpose of this study is twofold:

1. To analyze the clinical features of a cohort of patients with birdshot chorioretinopathy (BCR), an inflammatory bilateral ocular disease, affecting the choroid and the retina.

Various imaging techniques will be used to assess the effect of the disease on the retina and the choroid.

A standardized assessment of the visual function will be performed with visual acuity, visual field and color vision testing. The quality of life of the patients will be evaluated with the VFQ-25 questionnaire.

These analyses will help delineating different forms of the disease among its heterogeneous presentations.
2. To identify predisposing factors for the disease. The condition is unique from the immunogenetic standpoint by its association with the HLA-A29 allele, which is the strongest link between an HLA class I antigen and a disease. To date, however, the mechanisms leading to birdshot chorioretinopathy remain unknown. GWAS (Genome Wide association Study) based on DNA of the cohort patients will be performed with the aim to identify other susceptibility genes associated with BCR.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Bilateral disease 2. Presence of at least three peripapillary "birdshot lesions" inferior or nasal to the optic disk in one eye 3. Low-grade anterior segment intraocular inflammation (defined as ≤ 1+cells in the anterior chamber) 4. Low grade vitreous inflammatory reaction (defined as ≤ 2+ vitreous haze‡) Supportive findings 1\. HLA-A29 positivity 2. Retinal vasculitis 3. Cystoid macular edema Exclusion Criteria: 1. Keratic precipitates 2. Posterior synechiae 3. Presence of infectious, neoplastic, or other inflammatory diseases that can cause multifocal choroidal lesions

Primary outcome measure(s)

  • Best Corrected Visual Acuity (BCVA) — Through study completion, an average of 1 year
    Standard decimal clarity for distance visual acuity. It is expressed from 0 which is minimum \& worse value, corresponding to no light perception; to 1.0 (20/20) which is maximum \& best value
  • Visual field testing — Through study completion, an average of 1 year
    Humphrey 30-2 automated threshold perimetry with foveal sensitivity. It is expressed in Mean Deviation from -25 decibels or unachievable which is minimum \& worse value, to 0 decibel, which is maximum \& best value.
  • Color vision — Through study completion, an average of 1 year
    Assessed with Desaturated Lanthony 15-Hue Test: an objective technic evaluating sensitivity to color \& colour vision deficiency. Test result is categorized as Abnormal for minimum \& worse evaluation; and Normal for maximum \& best evaluation.
  • National Eye Institute 25-Item Visual Function Questionnaire — Through study completion, an average of 1 year
    Using a scale from 0 for minimum \& worse, to 100 for maximum \& best result; this questionnaire measures influence of visual impairment on various dimensions of quality of life such as emotional well-being and social functioning

Trial sites (1)

FacilityCityRegionStatus
Ophtalmopôle, Hôpital Cochin Paris Île-de-France Region Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05153057 on ClinicalTrials.gov ↗ ← All trials in France